HEALWELL AI Reaches 47 Peer-Reviewed Publications, Strengthening Its Scientific Moat for AI-Powered Real-World Clinical Evidence Generation

Executive Summary

• HEALWELL AI announced its 47th peer‑reviewed publication validating the DARWEN™ AI platform, including new research presented at the European Crohn's and Colitis Organisation (ECCO) meeting.
• The company secured three additional conference acceptances for 2026 covering inflammatory bowel disease, type 2 diabetes, and psoriasis, highlighting expanding collaborations with global life‑sciences partners.
• Management emphasized that each new publication creates a “compounding scientific and commercial moat,” generating further partnership inquiries and data‑access opportunities.

Key Details

• Total peer‑reviewed publications validating DARWEN™ AI: 47, spanning multiple disease areas and diverse patient populations.
• New research accepted for presentation at ECCO 2026; findings published in Journal of Crohn's and Colitis (Bressler et al., 2026).
• Additional 2026 conference acceptances:
• Treatment patterns of patients with inflammatory bowel disease.
• AI‑enabled clinical decision support to improve Type 2 diabetes quality standards in primary care.
• Suicidal ideation and behavior in plaque psoriasis patients receiving systemic therapies.
• Study conducted with the U.S. affiliate of a large pharmaceutical partner, demonstrating how AI‑enriched Canadian patient‑support data can generate real‑world evidence for U.S. medical affairs and market‑access initiatives.
• COO Sacha Gera highlighted that each publication drives new partnership inquiries, data access, and further research, reinforcing DARWEN™ AI’s commercial moat.
• CEO James Lee reiterated the strategy of building a scientific foundation to make DARWEN™ the default AI layer for real‑world evidence generation globally.

Notable Quotes

“The scientific team at HEALWELL continues to set the standard for clinically validated AI… Each publication generates new partnership inquiries, which generate new data access, which enables new publications, creating a compounding scientific and commercial moat that becomes harder to replicate with every study.” – Sacha Gera, Chief Operating Officer

“We are building the scientific foundation that will make DARWEN™ the default AI layer for real‑world evidence generation in global healthcare… With 47 peer‑reviewed publications and growing, we believe our clinically validated AI will play an increasingly important role…” – James Lee, Chief Executive Officer